TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya
Brief Summary: The purpose of this study is to determine the efficacy of pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children.


Options:
A: Arm Label: Group A (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group B (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group C (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group D (Granules); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Intervention Type: DRUG; Name: Pyronaridine-Artesunate; Assigned to Arm(s): Group A (Tablets), Group B (Tablets), Group C (Tablets), Group D (Granules)
B: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Arm Label: Artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-lumefantrine
C: Arm Label: pyronaridine/artesunate (6:2 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (9:3 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (12:4 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Intervention Type: DRUG; Name: pyronaridine/artesunate; Assigned to Arm(s): pyronaridine/artesunate (12:4 mg/kg), pyronaridine/artesunate (6:2 mg/kg), pyronaridine/artesunate (9:3 mg/kg)
D: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya
Brief Summary: The purpose of this study is to determine the efficacy of pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children.


Options:
A: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: Artesunate | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate + Mefloquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: Artesunate + Mefloquine; Assigned to Arm(s): arm 2
B: Arm Label: Pyramax; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): Pyramax
C: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate
D: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Arm Label: Artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-lumefantrine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya
Brief Summary: The purpose of this study is to determine the efficacy of pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children.


Options:
A: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Arm Label: Artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-lumefantrine
B: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
C: Arm Label: co-formulated Amodiaquine-Artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: amodiaquine-artesunate (AQAS) fixed-dose | Arm Label: artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination (AL) dispersable | Intervention Type: DRUG; Name: amodiaquine-artesunate (AQAS) fixed-dose; Assigned to Arm(s): co-formulated Amodiaquine-Artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination (AL) dispersable; Assigned to Arm(s): artemether-lumefantrine
D: Arm Label: Eurartesim dispersible oral tablets; Type: EXPERIMENTAL; Interventions: Drug: Eurartesim dispersible oral tablet | Arm Label: Eurartesim film coated tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: eurartesim film coated tablet | Intervention Type: DRUG; Name: Eurartesim dispersible oral tablet; Assigned to Arm(s): Eurartesim dispersible oral tablets | Intervention Type: DRUG; Name: eurartesim film coated tablet; Assigned to Arm(s): Eurartesim film coated tablet

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Quit4Baby: Reaching Pregnant Smokers With Health Information Via Text
Brief Summary: Despite the great health benefits associated with smoking cessation in pregnancy to both mother and baby, few studies to date have examined the applications of text messaging or other communication technologies for smoking cessation in this population. This project is the first step in developing a new dissemination strategy for reaching pregnant smokers. This research will explore how a state-of -the-art, interactive and intensive, text messaging program, SmokefreeMoms Text, can promote smoking cessation in pregnant smokers. This program may have the potential to reach pregnant smokers who are not currently being reached with traditional smoking cessation services. The study Aims are: 1) to elicit qualitative feedback from pregnant smokers and recent quitters (in the past month) about the concept of SmokefreeMoms, the proposed message protocols in SmokefreeMoms, and the proposed messages in SmokefreeMoms (Phase 1); 2) To develop and pilot test a prototype of SmokefreeMoms which is consistent with Clinical Practice Guidelines (Phase 2), and 3) To conduct a formative evaluation of SmokefreeMoms 1.0 with pregnant smokers and recent quitters (Phase 3). 4) To measure the likelihood that pregnant women who smoke cigarettes will join an SMS program by responding to different types of recruitment messages.


Options:
A: Arm Label: Intense follow up; Type: EXPERIMENTAL; Interventions: Behavioral: intense follow up | Arm Label: standard follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: intense follow up; Assigned to Arm(s): Intense follow up
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention (text); Type: EXPERIMENTAL; Interventions: Behavioral: SmokefreeMOM Text | Arm Label: Intervention Plus (text+quitline); Type: EXPERIMENTAL; Interventions: Behavioral: SmokefreeMOM Text | Intervention Type: BEHAVIORAL; Name: SmokefreeMOM Text; Assigned to Arm(s): Intervention (text), Intervention Plus (text+quitline)
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Reminders; Type: EXPERIMENTAL; Interventions: Behavioral: Reminders | Intervention Type: BEHAVIORAL; Name: Reminders; Assigned to Arm(s): Reminders
D: Arm Label: Nutrition messages; Type: EXPERIMENTAL; Interventions: Behavioral: SMS | Arm Label: General health messages; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS | Intervention Type: BEHAVIORAL; Name: SMS; Assigned to Arm(s): General health messages, Nutrition messages

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Quit4Baby: Reaching Pregnant Smokers With Health Information Via Text
Brief Summary: Despite the great health benefits associated with smoking cessation in pregnancy to both mother and baby, few studies to date have examined the applications of text messaging or other communication technologies for smoking cessation in this population. This project is the first step in developing a new dissemination strategy for reaching pregnant smokers. This research will explore how a state-of -the-art, interactive and intensive, text messaging program, SmokefreeMoms Text, can promote smoking cessation in pregnant smokers. This program may have the potential to reach pregnant smokers who are not currently being reached with traditional smoking cessation services. The study Aims are: 1) to elicit qualitative feedback from pregnant smokers and recent quitters (in the past month) about the concept of SmokefreeMoms, the proposed message protocols in SmokefreeMoms, and the proposed messages in SmokefreeMoms (Phase 1); 2) To develop and pilot test a prototype of SmokefreeMoms which is consistent with Clinical Practice Guidelines (Phase 2), and 3) To conduct a formative evaluation of SmokefreeMoms 1.0 with pregnant smokers and recent quitters (Phase 3). 4) To measure the likelihood that pregnant women who smoke cigarettes will join an SMS program by responding to different types of recruitment messages.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention (text); Type: EXPERIMENTAL; Interventions: Behavioral: SmokefreeMOM Text | Arm Label: Intervention Plus (text+quitline); Type: EXPERIMENTAL; Interventions: Behavioral: SmokefreeMOM Text | Intervention Type: BEHAVIORAL; Name: SmokefreeMOM Text; Assigned to Arm(s): Intervention (text), Intervention Plus (text+quitline)
B: Arm Label: texting group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: text messages focused on smoking cessation and pregnancy | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: text messages focused on smoking cessation and pregnancy; Assigned to Arm(s): texting group
C: Intervention Type: DRUG; Name: Sulfadoxine pyrimethamine; Assigned to Arm(s): N/A
D: Arm Label: Alma Sana Bracelet Arm; Type: EXPERIMENTAL; Interventions: Other: Alma Sana Bracelet | Arm Label: Simple Silicon Bracelet Arm; Type: EXPERIMENTAL; Interventions: Other: Simple Silicon Bracelet | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Alma Sana Bracelet; Assigned to Arm(s): Alma Sana Bracelet Arm | Intervention Type: OTHER; Name: Simple Silicon Bracelet; Assigned to Arm(s): Simple Silicon Bracelet Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Quit4Baby: Reaching Pregnant Smokers With Health Information Via Text
Brief Summary: Despite the great health benefits associated with smoking cessation in pregnancy to both mother and baby, few studies to date have examined the applications of text messaging or other communication technologies for smoking cessation in this population. This project is the first step in developing a new dissemination strategy for reaching pregnant smokers. This research will explore how a state-of -the-art, interactive and intensive, text messaging program, SmokefreeMoms Text, can promote smoking cessation in pregnant smokers. This program may have the potential to reach pregnant smokers who are not currently being reached with traditional smoking cessation services. The study Aims are: 1) to elicit qualitative feedback from pregnant smokers and recent quitters (in the past month) about the concept of SmokefreeMoms, the proposed message protocols in SmokefreeMoms, and the proposed messages in SmokefreeMoms (Phase 1); 2) To develop and pilot test a prototype of SmokefreeMoms which is consistent with Clinical Practice Guidelines (Phase 2), and 3) To conduct a formative evaluation of SmokefreeMoms 1.0 with pregnant smokers and recent quitters (Phase 3). 4) To measure the likelihood that pregnant women who smoke cigarettes will join an SMS program by responding to different types of recruitment messages.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention (text); Type: EXPERIMENTAL; Interventions: Behavioral: SmokefreeMOM Text | Arm Label: Intervention Plus (text+quitline); Type: EXPERIMENTAL; Interventions: Behavioral: SmokefreeMOM Text | Intervention Type: BEHAVIORAL; Name: SmokefreeMOM Text; Assigned to Arm(s): Intervention (text), Intervention Plus (text+quitline)
B: Arm Label: Personalized Reminder Texting (iTAB) + Psychoeducation; Type: EXPERIMENTAL; Interventions: Behavioral: individualized Texting for Adherence Building (iTAB) | Arm Label: Psychoeducation (CTRL); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducation | Intervention Type: BEHAVIORAL; Name: individualized Texting for Adherence Building (iTAB); Assigned to Arm(s): Personalized Reminder Texting (iTAB) + Psychoeducation | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Assigned to Arm(s): Psychoeducation (CTRL)
C: Arm Label: Kilkari; Type: EXPERIMENTAL; Interventions: Other: Kilkari | Arm Label: Comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Kilkari; Assigned to Arm(s): Kilkari
D: Arm Label: mHealth; Type: EXPERIMENTAL; Interventions: Other: mHealth | Arm Label: No mHealth; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: mHealth; Assigned to Arm(s): mHealth

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: McGrath Mac Videolaryngoscope Versus Macintosh Laryngoscope for Orotracheal Intubation in Critical Care Unit
Brief Summary: The aim of this study is to demonstrate that the rate of successful orotracheal intubation at first laryngoscopy will be higher in patients intubated with McGrath Mac videolaryngoscope compared to patients intubated with classical Macintosh laryngoscope in patients requiring an orotracheal intubation in ICU.


Options:
A: Arm Label: Macintosh laryngoscope; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tracheal intubation, Drug: Propofol and remifentanil anesthesia | Arm Label: McGrath Mac videolaryngoscope; Type: EXPERIMENTAL; Interventions: Procedure: Tracheal intubation, Drug: Propofol and remifentanil anesthesia | Intervention Type: PROCEDURE; Name: Tracheal intubation; Assigned to Arm(s): Macintosh laryngoscope, McGrath Mac videolaryngoscope | Intervention Type: DRUG; Name: Propofol and remifentanil anesthesia; Assigned to Arm(s): Macintosh laryngoscope, McGrath Mac videolaryngoscope
B: Arm Label: McGrath videolaryngoscopy; Type: EXPERIMENTAL; Interventions: Device: McGrath videolaryngoscopy | Arm Label: Direct laryngoscopy; Type: ACTIVE_COMPARATOR; Interventions: Device: Direct laryngoscopy | Intervention Type: DEVICE; Name: McGrath videolaryngoscopy; Assigned to Arm(s): McGrath videolaryngoscopy | Intervention Type: DEVICE; Name: Direct laryngoscopy; Assigned to Arm(s): Direct laryngoscopy
C: Arm Label: Videolaryngoscope McGrath Mac; Type: ACTIVE_COMPARATOR; Interventions: Device: Videolaryngoscope | Arm Label: Standard laryngoscope; Type: PLACEBO_COMPARATOR; Interventions: Device: Standard laryngoscope | Intervention Type: DEVICE; Name: Videolaryngoscope; Assigned to Arm(s): Videolaryngoscope McGrath Mac | Intervention Type: DEVICE; Name: Standard laryngoscope; Assigned to Arm(s): Standard laryngoscope
D: Arm Label: Laryngoscopy; Type: OTHER; Interventions: Procedure: Endotracheal Intubation | Arm Label: Videolaryngoscopy; Type: OTHER; Interventions: Procedure: Endotracheal Intubation | Intervention Type: PROCEDURE; Name: Endotracheal Intubation; Assigned to Arm(s): Laryngoscopy | Intervention Type: PROCEDURE; Name: Endotracheal Intubation; Assigned to Arm(s): Videolaryngoscopy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Controlled, Cross-over Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy
Brief Summary: This is a prospective, controlled, multi-country study to verifying the hypoallergenicity of the new amino acid-based formula in infants and children aged\< 12 years with documented cow's milk protein allergy (CMPA).


Options:
A: Arm Label: Lower protein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Higher protein formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Breastfed reference group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lower protein formula; Higher protein formula; Assigned to Arm(s): Higher protein formula, Lower protein formula
B: Arm Label: Control Study Formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Study Formula | Arm Label: Experimental Study Formula; Type: EXPERIMENTAL; Interventions: Other: Experimental Study Formula | Intervention Type: OTHER; Name: Control Study Formula; Assigned to Arm(s): Control Study Formula | Intervention Type: OTHER; Name: Experimental Study Formula; Assigned to Arm(s): Experimental Study Formula
C: Intervention Type: DRUG; Name: Parenteral Nutrition; Assigned to Arm(s): N/A
D: Arm Label: New Amino Acid formula; Type: EXPERIMENTAL; Interventions: Other: New Amino Acid formula | Arm Label: Control formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Commercially available Amino Acid Formula | Intervention Type: OTHER; Name: New Amino Acid formula; Assigned to Arm(s): New Amino Acid formula | Intervention Type: OTHER; Name: Commercially available Amino Acid Formula; Assigned to Arm(s): Control formula

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children
Brief Summary: Children hospitalized with severe illness in sub-Saharan Africa are at high risk of morbidity and mortality following discharge from hospital. These children represent an accessible high-risk population in which targeted interventions to prevent morbidity and mortality could have dramatic impact. A large cluster randomized trial of azithromycin delivered in a mass drug administration program within trachoma endemic areas in sub-Saharan Africa demonstrated an almost 50% mortality benefit in children 1-9 years of age in treated communities. However, mass drug administration of azithromycin leads to the rapid emergence of macrolide resistance within treated communities and is expensive. The targeted delivery of azithromycin to children at hospital discharge may be a novel and practical intervention to maximize benefit while minimizing risk of antibiotic resistance. This is a randomized, double-blind, placebo-controlled trial to determine the efficacy of azithromycin provided at discharge, compared to placebo, in reducing mortality and re-hospitalization rates in children age 1-59 months in Kenya. The study will also investigate potential mechanisms by which azithromycin may reduce morbidity and mortality in this population and will assess the emergence of antibiotic resistance among treated individuals and their primary caregivers. A cost-effectiveness analysis of the intervention will also be conducted.


Options:
A: Intervention Type: DRUG; Name: Erythromycin; Assigned to Arm(s): N/A
B: Arm Label: Physiologic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Erythromycine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Physiologic saline | Intervention Type: DRUG; Name: Erythromycin; Assigned to Arm(s): Erythromycine
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Azithromycin (Zithromax); Type: EXPERIMENTAL; Interventions: Drug: Zithromax | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zithromax; Assigned to Arm(s): Azithromycin (Zithromax) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of a Brief Intervention for Medically Hospitalized Suicide Attempt Survivors
Brief Summary: The current study proposes to study the feasibility and acceptability of a brief psychosocial intervention delivered to suicide attempt survivors hospitalized on a medical/surgical floor or inpatient psychiatry unit at Vanderbilt University Medical Center. The proposed study will involve training of care providers affiliated with Vanderbilt University Medical Center to deliver the brief intervention. Additionally, the participants will complete baseline, 1, 3, and 12-month assessments on outcomes of interest, including readiness to change problematic behaviors, engagement in outpatient mental health services, suicidal ideation, self-harming behavior, and reasons for living.


Options:
A: Arm Label: Dialectical Behavior Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy; Assigned to Arm(s): Dialectical Behavior Therapy
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Group 1, Group 2
C: Arm Label: Care as Usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Teachable Moment Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Teachable Moment Brief Intervention | Intervention Type: BEHAVIORAL; Name: Teachable Moment Brief Intervention; Assigned to Arm(s): Teachable Moment Brief Intervention
D: Arm Label: Selegiline; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: Placebo (for Selegiline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Selegiline) | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): Selegiline | Intervention Type: DRUG; Name: Placebo (for Selegiline); Assigned to Arm(s): Placebo (for Selegiline)

Answer: C